ESPRIT study design and outcomes – a critical appraisal

• Published in: Current medical research and opinion Vol. 23; no. 2; pp. 271 - 273
• Main Author: Einhäupl, Karl
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.02.2007; Taylor & Francis; Informa Healthcare
• Subjects: Aspirin; Aspirin - administration & dosage; Aspirin - adverse effects; Aspirin - therapeutic use; Biomarkers; Brain Ischemia - epidemiology; Brain Ischemia - prevention & control; Dipyridamole; Dipyridamole - administration & dosage; Dipyridamole - adverse effects; Dipyridamole - therapeutic use; Drug Therapy, Combination; Fibrinolytic Agents - administration & dosage; Fibrinolytic Agents - adverse effects; Fibrinolytic Agents - therapeutic use; Hemorrhage - chemically induced; Hemorrhage - epidemiology; Humans; Ischaemic stroke; Methodological issues; Myocardial Infarction - epidemiology; Myocardial Infarction - prevention & control; Outcome study; Patient Dropouts - statistics & numerical data; Prospective Studies; Research Design; Secondary prevention; Stroke - epidemiology; Stroke - prevention & control; Treatment Outcome; Vascular Diseases - mortality

ABSTRACT Evidence is needed to guide therapeutic decisions on patients who had ischaemic cerebral events. The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomi...